Nasdaq:US$18.72 (-0.96) | HKEX:HK$29.65 (-0.70) | AIM:£3.04 (-0.09)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 15 Oct 2017

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC

JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116)

Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su

Venue: IASLC 18th World Conference on Lung Cancer
Session: JCSE 01 – Joint IASLC / CSCO / CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West (ID 630)
Presenter: J Zhou
Date: Sunday, October 15, 2017

For a summary of the data presented, please see the company overview presentation.